Quindoline

Quindoline

SCHEMBL191243

c1ccc2nc3c(cc2c1)[nH]c1ccccc13

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
POLB P06746 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
TP53 P04637 2/20 0.58
CASP1 P29466 2/20 0.58
MAPK10 P53779 2/20 0.58
CASP7 P55210 2/20 0.58
MEN1 O00255 1/20 0.55
APAF1 O14727 1/20 0.55
RAD52 P43351 1/20 0.55
KMT2A Q03164 1/20 0.55
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 2/20 0.46
GPR3 P46089 1/20 0.46
MAPT P10636 4/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quindoline SCHEMBL30805772 1.00 NPC1 (0.58) NPC1RAB9APOLBSMN1; SMN2TP53
Quindoline SCHEMBL8478837 0.98 NPC1 (0.56) NPC1RAB9APOLBSMN1; SMN2TP53
Quindoline SCHEMBL8481282 0.98 NPC1 (0.56) NPC1RAB9APOLBSMN1; SMN2TP53
Acridine SCHEMBL28191835 0.82 ALDH1A1 (0.62) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL4505367 0.82 TDO2 (0.53) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL8478861 0.82 NPC1 (0.62) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL2112432 0.82 NPC1 (0.55) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL24621698 0.80 NPC1 (0.40) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL633820 0.80 PARP1 (0.53) NPC1RAB9APOLBSMN1; SMN2TP53
SCHEMBL24621438 0.79 NPC1 (0.39) NPC1RAB9APOLBSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559499-B2 Uses of compounds having anti-HSV-1 activity ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2026-02-24 US claimed
CN-113956232-B Quinoline-bisindole compound and preparation method and application thereof 山东师范大学 2022-09-16 CN claimed
US-20220105083-A1 USES OF COMPOUNDS HAVING ANTI-HSV-1 ACTIVITY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-04-07 US claimed
CN-113956232-A Quinoline-bisindole compound and preparation method and application thereof 山东师范大学 2022-01-21 CN claimed
WO-2021105761-A1 COMPOSITIONS AND THEIR USES FOR TREATING CANCERS INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) 2021-06-03 WO claimed
WO-2020160174-A1 USES OF COMPOUNDS HAVING ANTI-HSV-1 ACTIVITY UNIVERSITA DEGLI STUDI DI PADOVA (IT) 2020-08-06 WO claimed
CN-108752339-B A kind of synthetic method of quindoline and its derivative 武汉工程大学 2019-10-22 CN claimed
CN-108752339-A A kind of synthetic method of quindoline and its derivative 武汉工程大学 2018-11-06 CN claimed
CN-108558878-A A kind of synthesis technology of quindoline and its derivative 武汉工程大学 2018-09-21 CN claimed
US-9960356-B2 Organic electroluminescence device, lighting equipment and display device Konica Minolta, Inc. (JP) 2018-05-01 US claimed
US-20150166886-A1 FLUORESCENCE AND DELAYED FLUORESCENCE-TYPE ORGANIC LIGHT-EMITTING MATERIAL AND ELEMENT KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2015-06-18 US claimed
US-7439271-B2 Reduction of hair growth THE GILLETTE COMPANY (US) 2008-10-21 US claimed
US-20030012755-A1 Reduction of hair growth GILLETTE COMPANY, THE 2003-01-16 US claimed
WO-1994018203-A1 ALKALOID COMPOUNDS EXTRACTED FROM CRYPTOLEPIS SANQUINOLENTA AND USES THEREOF HEALTHSEARCH, INC. (US) 1994-08-18 WO claimed
US-20260114114-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND COMPOSITION FOR ORGANIC MATERIALS MERCK PATENT GMBH (DE) 2026-04-23 US disclosed
US-12559499-B2 Uses of compounds having anti-HSV-1 activity ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2026-02-24 US disclosed
US-12559459-B2 Aromatic heterocyclic derivative, and organic electroluminescent element, illumination device, and display device using aromatic heterocyclic derivative MERCK PATENT GMBH (DE) 2026-02-24 US disclosed
WO-1996010015-A1 CRYPTOLEPINE ANALOGS WITH HYPOGLYCEMIC ACTIVITY SHAMAN PHARMACEUTICALS, INC. (US) 1996-04-04 WO disclosed
US-5362726-A Spiro-nonacyclic indoloquinoline alkaloid, cryptospirolepine HEALTHSEARCH, INC. (US) 1994-11-08 US disclosed
WO-1994018203-A1 ALKALOID COMPOUNDS EXTRACTED FROM CRYPTOLEPIS SANQUINOLENTA AND USES THEREOF HEALTHSEARCH, INC. (US) 1994-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220105083-A1 USES OF COMPOUNDS HAVING ANTI-HSV-1 ACTIVITY HDAC1, HDAC7, HDAC6 NPC1 1011/4885RAB9A 1440/4885POLB 685/4885
US-12559459-B2 Aromatic heterocyclic derivative, and organic electroluminescent element, illumination device, and display device using aromatic heterocyclic derivative NR2E3, CDYL, TYR NPC1 4735/4885RAB9A 2749/4885POLB 4344/4885
US-20260114114-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND COMPOSITION FOR ORGANIC MATERIALS LEF1, AP2A1, CACNA2D1 NPC1 3746/4885RAB9A 3751/4885POLB 1552/4885
US-20150166886-A1 FLUORESCENCE AND DELAYED FLUORESCENCE-TYPE ORGANIC LIGHT-EMITTING MATERIAL AND ELEMENT LEF1, EML4, TEAD1 NPC1 3075/4885RAB9A 4391/4885POLB 3255/4885
US-12559499-B2 Uses of compounds having anti-HSV-1 activity TOP1, CDK7, TOP2B NPC1 2537/4885RAB9A 1041/4885POLB 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.